302 related articles for article (PubMed ID: 28612140)
1. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Patel SP; Kim DW; Bassett RL; Cain S; Washington E; Hwu WJ; Kim KB; Papadopoulos NE; Homsi J; Hwu P; Bedikian AY
Cancer Immunol Immunother; 2017 Oct; 66(10):1359-1366. PubMed ID: 28612140
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
3. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
[TBL] [Abstract][Full Text] [Related]
4. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Patel PM; Suciu S; Mortier L; Kruit WH; Robert C; Schadendorf D; Trefzer U; Punt CJ; Dummer R; Davidson N; Becker J; Conry R; Thompson JA; Hwu WJ; Engelen K; Agarwala SS; Keilholz U; Eggermont AM; Spatz A;
Eur J Cancer; 2011 Jul; 47(10):1476-83. PubMed ID: 21600759
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Tas F; Argon A; Camlica H; Topuz E
Melanoma Res; 2005 Dec; 15(6):543-8. PubMed ID: 16314741
[TBL] [Abstract][Full Text] [Related]
6. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Clark JI; Moon J; Hutchins LF; Sosman JA; Kast WM; Da Silva DM; Liu PY; Thompson JA; Flaherty LE; Sondak VK
Cancer; 2010 Jan; 116(2):424-31. PubMed ID: 19918923
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Tarhini A; Lin Y; Lin H; Rahman Z; Vallabhaneni P; Mendiratta P; Pingpank JF; Holtzman MP; Yusko EC; Rytlewski JA; Rao UNM; Ferris RL; Kirkwood JM
J Immunother Cancer; 2018 Oct; 6(1):112. PubMed ID: 30352626
[TBL] [Abstract][Full Text] [Related]
15. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R; Seifert B; Simcock M; Goldinger SM; Gillessen S; Ochsenbein A; Michielin O; Cathomas R; Schläppi M; Moch H; Schraml PH; Mjhic-Probst D; Mamot C; Schönewolf N; Dummer R;
Ann Oncol; 2012 Feb; 23(2):531-6. PubMed ID: 21527587
[TBL] [Abstract][Full Text] [Related]
16. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
17. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
18. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
Danielli R; Cisternino F; Giannarelli D; Calabrò L; Camerini R; Savelli V; Bova G; Dragonetti R; Di Giacomo AM; Altomonte M; Maio M
Expert Opin Biol Ther; 2018 Jul; 18(sup1):77-83. PubMed ID: 30063847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]